ArticleDiagnostics (Basel, Switzerland)2021
Salvaging Detection of Early-Stage Ovarian Malignancies When CA125 Is Not Informative.
Article in Diagnostics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Morphological and molecular characterization of epithelial ovarian cancer: SEOM-SEAP consensus guidelines for biomarker integration in clinical practice.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Guideline
- Doppel as an early-stage biomarker promoting EMT and dissemination in ovarian cancers.International journal of cancer · 2026Article
- Special Issue "Biomarkers and Early Detection Strategies of Ovarian Tumors".International journal of molecular sciences · 2025Article
- Differential diagnosis of benign and malignant ovarian tumors with combined tumor and systemic inflammation-related markers.Journal of Cancer · 2025Article
- Value of miR200b and its combination with other biochemical markers in the diagnosis of epithelial ovarian cancer.Molecular biology reports · 2024Article
- ReClassification of Patients with Ambiguous CA125 for Optimised Pre-Surgical Triage.Diagnostics (Basel, Switzerland) · 2024Article
- Review
- Association Between Systemic Immune-Inflammation Index and CA125 in Older Women: Insights from a Cross-Sectional NHANES Study.International journal of women's health · 2024Article
- OvaPrint-A Cell-free DNA Methylation Liquid Biopsy for the Risk Assessment of High-grade Serous Ovarian Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Evaluation of the Potential Diagnostic Utility of the Determination of Selected Immunological and Molecular Parameters in Patients with Ovarian Cancer.Diagnostics (Basel, Switzerland) · 2023Review
- Review
- Molecular Biomarkers for the Early Detection of Ovarian Cancer.International journal of molecular sciences · 2022Review
- Defining Models to Classify between Benign and Malignant Adnexal Masses Using Routine Laboratory Parameters.Cancers · 2022Article
- Biomarker-Based Models for Preoperative Assessment of Adnexal Mass: A Multicenter Validation Study.Cancers · 2022Article
- Perspectives on Ovarian Cancer 1809 to 2022 and Beyond.Diagnostics (Basel, Switzerland) · 2022Article
- Comparison of HE4, CA125, ROMA and CPH-I for Preoperative Assessment of Adnexal Tumors.Diagnostics (Basel, Switzerland) · 2022Article
- Management of the Adnexal Mass: Considerations for the Family Medicine Physician.Frontiers in medicine · 2022Article
- Current clinical application of serum biomarkers to detect and monitor ovarian cancer - update.Przeglad menopauzalny = Menopause review · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOvarian cancer is the deadliest gynecologic cancer, with no recommended screening test to assist with early detection. Cancer antigen 125 (CA125) is a serum biomarker commonly used by clinicians to assess preoperative cancer risk, but it underperforms in premenopausal women, early-stage malignancies, and several histologic subtypes. OVA1 is a multivariate index assay that combines CA125 and four other serum proteins to assess the malignant risk of an adnexal mass.
objectiveTo evaluate the performance of OVA1 in a cohort of patients with low-risk serum CA125 values. STUDY
designWe analyzed patient data from previous collections (N = 2305, prevalence = 4.5%) where CA125 levels were at or below 67 units/milliliter (U/mL) for pre-menopausal women and 35 U/mL for post-menopausal women. We compare the performance of OVA1 to CA125 in classifying the risk of malignancy in this cohort, including sensitivity, specificity, positive and negative predictive values.
resultsThe overall sensitivity of OVA1 in patients with a low-risk serum CA125 was 59% with a false-positive rate of 30%. OVA1 detected over 50% of ovarian malignancies in premenopausal women despite a low-risk serum CA125. OVA1 also correctly identified 63% of early-stage cancers missed by CA125. The most common epithelial ovarian cancer subtypes in the study population were mucinous (25%) and serous (23%) carcinomas. Despite a low-risk CA125, OVA1 successfully detected 83% of serous, 58% of mucinous, and 50% of clear cell ovarian cancers.
conclusionsAs a standalone test, CA125 misses a significant number of ovarian malignancies that can be detected by OVA1. This is particularly important for premenopausal women and early-stage cancers, which have a much better long-term survival than late-stage malignancies. Using OVA1 in the setting of a normal serum CA125 can help identify at-risk ovarian tumors for referral to a gynecologic oncologist, potentially improving overall survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.